Osmetech and Qiagen Sign Development and Supply Agreement
Osmetech, the international molecular diagnostics business, has signed an agreement with Qiagen, pursuant to which Osmetech will adapt a QIAplex-based respiratory viral test for use on Osmetech’s recently launched eSensor XT-8 molecular diagnostics system.
Under the terms of the agreement, Qiagen will supply proprietary QIAplex-based reagents for the multiplex amplification of the most common viruses associated with respiratory infections.
Qiagen has previously launched its next generation, QIAplex-based ResPlex II respiratory panel only for research use. Osmetech intends to develop an in-vitro diagnostic test for use on its eSensor XT-8 molecular diagnostic instrument and to submit this test to the FDA for 510(k) clearance.
James White, CEO of Osmetech, said: “We are delighted that Qiagen has partnered with Osmetech. This is an excellent opportunity to take an already commercially successful product into the mainstream diagnostics market, illustrating the attraction of our easy to use eSensor XT-8 instrument. This is another opportunity to broaden our test menu and establish the eSensor XT-8 as a leading molecular diagnostics platform.”